Lilly Bolsters GLP-1 Supply Chain, Pledging $3 Billion Manufacturing Expansion in China

Eli Lilly announced plans to invest $3 billion in China over the next decade.¹ This capital infusion is primarily directed toward building production capacity for orforglipron, the company’s highly anticipated experimental oral non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of type 2 diabetes and obesity.¹ The drugmaker confirmed it submitted a marketing application for orforglipron to China’s National Medical Products Administration at the end of 2025.²

This latest commitment brings Lilly’s total investment in China to approximately $6 billion.² A critical component of this expansion involves the establishment of a localized manufacturing and supply system for oral solid dosage forms, a shift from the injectable delivery systems that currently define the GLP-1 market.²

Highlighting the strategic importance of this regional growth, Eli Lilly vice president and general manager of China, Huzur Devletsah, said in the press release “the increased investment in Beijing signifies our continued commitment to improving our full-value-chain supply system in China to better meet the growing needs of Chinese patients.”²

How Will Lilly Scale Capacity Through Regional Hubs and Collaborations?

The $3 billion investment will be executed through a combination of internal facility upgrades and external strategic partnerships. Lilly’s existing Suzhou manufacturing site, established in 1996, will see an expansion of its incretin injection production capacity.² This facility has already been a focal point of activity, having received a $212 million investment in October 2024 to increase production for existing diabetes and obesity medications.²

In addition to expanding the Suzhou hub, Lilly is adding oral solid dosage form production capacity in Beijing.² To further accelerate its supply chain readiness, the company is entering collaborations with multiple local production partners. The first of these is a $200 million collaboration with Pharmaron, a prominent Chinese contract development and manufacturing organization.³ This multifaceted approach underscores the company’s intent to build a robust, redundant supply chain capable of meeting the massive projected demand for oral GLP-1 therapies.

What Is the Clinical Profile and Market Forecast for Orforglipron?

The move to bolster manufacturing comes as orforglipron demonstrates strong clinical potential. In late-stage trials, the once-daily oral treatment helped overweight adults without diabetes lose 12.4% of their body weight over 72 weeks at the highest dose.¹ Furthermore, clinical data suggests that orforglipron can help maintain weight loss in patients who switch from injectable GLP-1 treatments, such as Lilly’s Zepbound or Novo Nordisk’s Wegovy.¹

Industry analysts at GlobalData forecast that orforglipron could generate global sales of $13 billion by 2031, provided it receives regulatory approval.² The transition to an oral format is expected to significantly reduce barriers to patient adherence and simplify the logistics of the pharma supply chain.

Lilly’s expansion in China is part of a broader, $27 billion global investment drive, aimed at revolutionizing its manufacturing footprint.² This includes the construction of four new facilities in the United States, at least three of which are confirmed production hubs for weight−loss therapies. To mitigate immediate supply risks, Lilly has already accumulated nearly $550 million worth of orforglipron-related inventory in the US.²

The decision to deepen ties with China occurs during a period of shifting pharmaceutical investment in the region. While firms like AstraZeneca and Haleon have also announced manufacturing investments this year, Bristol Myers Squibb has moved to divest, selling a 60% stake in a Shanghai-based joint venture in late 2025.¹ Notably, Lilly’s announcement was timed just ahead of a high-profile summit between US President Donald Trump and China’s Xi Jinping.¹

References

1. Reuters. Eli Lilly to invest $3 billion in China, seeks approval for weight loss pill. Reuters. March 11, 2026. Accessed March 12, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-invest-3-billion-china-over-next-decade-2026-03-11/.
2. Barrie R. Eli Lilly to invest $3bn in China in anticipation of orforglipron approval. Yahoo Finance. March 11, 2026. Accessed March 12, 2026. https://finance.yahoo.com/news/eli-lilly-invest-3bn-china-153144940.html.
3. Chau J. Pharmaron Beijing shares jump after Eli Lilly pledges $200 million investment in partnership. MarketWatch.Published March 12, 2026. Accessed March 12, 2026. https://www.marketwatch.com/story/pharmaron-beijing-shares-jump-after-eli-lilly-pledges-200-million-investment-in-partnership-70a306c0